When Is an AI Agent Ready for Deployment?
A critical review of READY’s deployment qualification framework, its clinical-audit results, and the assumptions behind human oversight and statistical confidence.
The paper
READY or Not: Reliable Enterprise Agent Deployment — Chatrath, Veronica; Zhu, Bryan; Fan, Jingxuan; Pu, George; Tiwari, Soham Dinesh; Dan, Soham; Young, Ryan; Yuan; Li; Yao, Yuang; Shanker, Apaar; Yang, Minglai; Zhang, Daniel Yue; He, Yunzhong; Liu, Ying; Wang, Chenguang; Yin, Zhijun; Xue, Yuan.
arXiv:2609.02095v1 · Artificial Intelligence (cs.AI). First submitted 2026-09-02; reviewed version dated 2026-09-02. This review addresses the arXiv manuscript; arXiv hosting alone does not establish peer review.
Contribution
Source-derived synopsis. Chatrath and colleagues’ READY or Not: Reliable Enterprise Agent Deployment, version 1 proposes a way to qualify an AI agent together with an oversight policy for a particular workflow. It selects a policy against a reliability target and cost model using development cases, freezes the policy, and evaluates it on held-out cases. In a retrospective clinical-audit benchmark, 16 systems each ran on 750 cases. The primary analysis routed completed reports to review using the agents’ stated confidence and assumed that review succeeded 90% of the time. At a 76% reliability target, Sonnet 5 and GPT-5.4 qualified with 29.6% and 39.2% of held-out cases routed to review, respectively, despite development-set autonomous accuracies of 72.5% and 72.8%. The reported qualifications are conditional on the review assumption. The broader framework also proposes evaluating interventions during execution, but the paper leaves large-scale empirical validation of those policies to future work.
Original analysis. READY’s useful shift is to make the unit of evaluation a specified human–AI arrangement. A system’s autonomous score cannot tell an organization how many cases a proposed routing rule will send to reviewers, whether the resulting work meets its chosen target, or what assumptions support that conclusion. Those questions matter for accountability because the organization must choose the success criterion, target, review process and acceptable costs. The resulting profile makes those choices available for scrutiny; it does not itself determine whether they are appropriate.
The clinical example also shows why a target is a governance decision. A 76% target is the paper’s comparison point, not evidence that this level is acceptable for clinical use. Decision-makers would need to explain the consequences of different errors and who bears them before using an aggregate target as a deployment criterion. The site’s Human Oversight of AI Systems page adds a complementary question: whether reviewers have the context and authority to challenge or interrupt an automated process. READY makes review burden measurable in its example, while the supplied experiment does not measure those conditions.
Evidence
Original analysis. The study’s case-level split is a strength: thresholds were selected on 375 development cases and evaluated on the same 375 held-out cases for each system. It compares policies on a common cohort and keeps the principal threshold selection separate from qualification. The five-percentage-point selection margin also makes the chosen policies more conservative than selecting directly at the target. A held-out result remains conditional on the represented cases, the frozen rule and the declared review model.
The comparison between the two near-tied agents is informative, but review percentage at one target is not a complete ranking. A threshold can move only between the confidence values a system actually emits; a coarse signal can push a policy past the target. The paper reports that Gemini-3.1-Pro qualified at the selected target only by routing every case to review. Its appendix also reports a class-based control that, on this benchmark, was not consistently more expensive than confidence-only routing. These observations limit any simple conclusion that one signal or policy will always use less oversight.
The distinction between measured and assumed performance is decisive. The case study did not execute the declared human-review path on every escalated case. Its 90% review-success value is an assumption, not a measured clinician success rate. At full review, the reported reliability equals that assumption; the agent contributes no autonomously accepted cases. The paper’s sensitivity analysis shows how changing the assumed review success changes the selected policies and their review burden. It cannot establish which assumption holds in a particular institution.
There is also a statistical issue worth resolving before relying on the reported confidence bounds. The general method says qualification should account for variation in both accepted-case success and the fraction routed to review. The appendix’s stated calculation applies a binomial lower bound to accepted-case success while weighting it by the observed routing fraction. Original analysis: that description appears to treat the observed fraction as fixed, leaving unclear whether the reported bound captures all the sampling variation the general method calls for. The supplied text does not establish how much this affects any reported qualification; an independent statistical check is needed.
Proposed tests. A prospective evaluation could run the frozen routing policy with actual reviewers, record their decisions and time, and measure success on the cases the policy selects. It could compare those outcomes with the assumed 90% review rate, including uncertainty and differences across case types. A separate statistical check could compare the reported bound with a prespecified bound for the full case-level policy outcome, accounting for routing-fraction variation and any clustering. These are proposed tests, not results from the paper.
Limitations and relevance
Original analysis. The main clinical measure is agreement with a four-way reference verdict. A process-aware sensitivity analysis also counts disqualifying defects and changes the deployment picture substantially: mean review burden across the reported target sweep rises from 53.0% to 69.8%. The choice of success definition therefore affects the practical claim. A correct verdict alone may leave an evidential or procedural defect outside the primary measure; conversely, adding a defect rule requires confidence that the rule captures what matters for the workflow.
READY allows additional constraints for severe failures, but the primary analysis treats success as a binary outcome. That makes it possible for different kinds of failure to enter the aggregate rate alike. A workflow owner should specify serious failure categories and examine whether the available sample can support claims about them. The paper’s proposed tail-risk machinery is a framework extension; the clinical results supplied here do not demonstrate that rare severe harms have been adequately measured.
Oversight also has costs beyond a fraction of cases. Review time, expertise, access to evidence, correction work and the ability to stop or reverse an action could change both the cost and effectiveness of a policy. Hypothetical example: two reviewers might each receive the same number of cases, while one must reconstruct missing evidence and the other receives a complete record. Equal review rates would not establish equal workload or equal oversight. The paper’s general cost model can represent varying costs, but this example should not be read as an observation from its study.
Proposed test. Future evaluations could report reviewer time and recovery work alongside model execution and infrastructure use, including the resources required for logging and repeated evaluation. They could then ask whether a policy that looks inexpensive under a constant review-cost assumption remains attractive when those costs are measured. The supplied study does not provide a material energy or infrastructure comparison.
For a review concerned with human agency and accountable AI, READY offers a concrete way to expose deployment assumptions and challenge a capability-only score. Its strongest empirical contribution is the retrospective clinical-audit comparison under a narrow terminal routing policy. It does not establish that live human–AI teams achieve the assumed reliability, that the selected target is appropriate, or that the method proves a spiritual doctrine. The next evidential step is to test the actual people, workflow and consequences to which a deployment claim would apply.
AI-use disclosure
This review was drafted by GPT-6.1 Terra with high reasoning and checked in a separate GPT-6.1 Sol session with medium reasoning. Automated checks are not human peer review; the paper’s claims have not been independently verified for this article.
Paper sources
Bibliographic metadata checked 2026-10-27.